CISAPRIDE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H29ClFN3O4
Molecular Weight	465.945
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C3=C(OC)C=C(N)C(Cl)=C3

InChI

InChIKey=DCSUBABJRXZOMT-IRLDBZIGSA-N

InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H29ClFN3O4
Molecular Weight	465.945
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.rxlist.com/propulsid-drug.htm
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/propulsid.html | http://www.marvistavet.com/cisapride.pml

Cisapride is chemically related to metoclopramide, but unlike metoclopramide, it does not cross the blood-brain barrier or have antidopaminergic effects. Cisapride is a serotonin-4 (5-HT4) receptor agonist. Cisapride was indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. The Food and Drug Administration (FDA) in America stopped the marketing of cisapride as of 14th July 2000. They had received at least 341 reports of heart rhythm abnormalities and these led to 80 deaths. Other reported adverse effects are: headache, diarrhea, abdominal pain, nausea, constipation. Cisapride for animals has been found helpful in some cases of megaesophagus and is a common treatment for feline megacolon. Clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride. Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 4 (5-HT4) receptor 39 Target ID: CHEMBL1875 Sources: http://www.rxlist.com/propulsid-drug.htm	Agonist 2678	41.5 nM [Ki]
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10780971	Substrate 661
Cytochrome P450 2A6 16 Target ID: CHEMBL5282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10780971	Substrate 661

Conditions

Condition	Modality	Highest Phase	Product
Gastroesophageal reflux disease 59 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf	Palliative	Withdrawn	PROPULSID Approved Use Cisapride is indicated for the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease. Launch Date 7.4390399E11
Megacolon 3 Sources: https://cdn.ymaws.com/www.aavpt.org/resource/resmgr/imported/cisapride.pdf	Primary	Not Provided 504	Unknown Approved Use Unknown
Constipation 112 Sources: https://cdn.ymaws.com/www.aavpt.org/resource/resmgr/imported/cisapride.pdf	Primary	Not Provided 504	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
7.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
75.7 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
115.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
190.4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
69.5 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
88.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1193 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1925 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2978 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
719 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
8.2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	NORCISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.77 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg 4 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
8.98 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	20 mg 4 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
9.76 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	40 mg 4 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020210_S000_Cisapride_BIOPHARMR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	CISAPRIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Co-administed with:: erythromycin Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 1 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Arrhythmia... Other AEs: Arrhythmia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 58000 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 58000 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Diarrhea... Other AEs: Diarrhea (12 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
2 mg/kg 4 times / day steady, oral Studied dose Dose: 2 mg/kg, 4 times / day Route: oral Route: steady Dose: 2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 2 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	Other AEs: Arrhythmia... Other AEs: Arrhythmia (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/

AEs

AE	Significance	Dose	Population
Arrhythmia	1 patient	0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Co-administed with:: erythromycin Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 1 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
Diarrhea	12 patients	0.2 mg/kg 4 times / day steady, oral Recommended Dose: 0.2 mg/kg, 4 times / day Route: oral Route: steady Dose: 0.2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 58000 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 58000 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/
Arrhythmia	2 patients	2 mg/kg 4 times / day steady, oral Studied dose Dose: 2 mg/kg, 4 times / day Route: oral Route: steady Dose: 2 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/	healthy, newborns n = 2 Health Status: healthy Condition: premature infants, <36 weeks Age Group: newborns Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/9925843/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461	P-gp 1537 CYP1A2 1054 CYP2C19 991 CYP2A6 543 CYP2E1 667

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/10859153/	yes [Ki 14 uM]
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/12621386/	yes [Ki 16.1 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12621386/	no
CYP1A2 1054	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2A6 543	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2C19 991	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2D6 1217	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP2E1 667	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246	yes
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf#page=10;https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246 Page: 10.0	yes	yes (co-administration study) Comment: Ketoconazole resulted in an 8 fold increase and fluconazole more than doubled the AUC of cisapride. Many other DDIs: see https://pubmed.ncbi.nlm.nih.gov/10926350/ Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20767-S011_Propulsid.pdf#page=10;https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1038/sj.bjp.0703246 Page: 10.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/9374794/

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific, Inc. (AKSCI)	3553AH	http://www.aksci.com/item_detail.php?cat=3553AH
Alfa Chemistry	AP260779882-A	https://reagents.alfa-chemistry.com/product/cisapride-cas-260779-88-2-8872.html
Alfa Chemistry	AP260779882-B	https://reagents.alfa-chemistry.com/product/cisapride-monohydrate-cas-260779-88-2-8873.html
Alichem	129009439	http://www.alichem.com/en/products/260779-88-2.html
Aurora Fine Chemicals LLC	A17.904.038	http://online.aurorafinechemicals.com/info?ID=A17.904.038
AvaChem Scientific	2794H	http://www.avachem.com/productSearch.asp?2794H
BOC Sciences	260779-88-2	https://www.bocsci.com/cisapride-hydrate-cas-260779-88-2-item-103946.html
Chemspace	CSSB00020619548	https://chem-space.com/CSSB00020619548
Clearsynth	CS-O-15504	https://www.clearsynth.com/en/CSO15504.html
Glentham Life Sciences	GL0434	http://www.glentham.com/products/product/GL0434/
Lab Network	LN01806108	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01806108
MolPort	MolPort-016-638-372	https://www.molport.com/shop/molecule-link/MolPort-016-638-372
MolPort	MolPort-044-674-489	https://www.molport.com/shop/molecule-link/MolPort-044-674-489
Selleck Chemicals	S4751	http://www.selleckchem.com/products/cisapride.html
Sigma-Aldrich	C4740_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c4740?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1134120_USP	https://www.sigmaaldrich.com/catalog/product/usp/1134120?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S567175	https://www.smolecule.com/products/s567175
abcr GmbH	AB511558	http://www.abcr.de/shop/en/AB511558

PubMed

Title	Date	PubMed
Efficacy and tolerability of cisapride in children.	2001	11577921
Comparative safety of the different macrolides.	2001	11574199
Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole.	2001	11510629
Gastroesophageal reflux in infants and children.	2001	11480761
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.	2001	11419561
Saquinavir soft gelatin capsule: a comparative safety review.	2001	11347724
[The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].	2001	11344699
Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study.	2001 Apr	11396814
Synergistic and antagonistic pharmacodynamic interaction between ranitidine and cisapride: a study on the isolated rabbit intestine.	2001 Apr	11352537
Electrogastrography: a non-invasive measurement of gastric function.	2001 Apr-Jun	11491049
The effect of cisapride on the corrected QT interval and QT dispersion in premature infants.	2001 Aug	11568520
Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats.	2001 Aug	11555327
Gastrointestinal tract cytomegalovirus infection with prolonged vomiting and fever in an immunocompetent child.	2001 Aug	11519392
Enteral feeding in the critically ill: comparison between the supine and prone positions: a prospective crossover study in mechanically ventilated patients.	2001 Aug	11511335
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.	2001 Aug	11510389
No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease.	2001 Aug	11507354
Survey of primary care physicians' approach to gastroesophageal reflux disease in elderly patients.	2001 Aug	11487605
Cisapride does not improve precolonoscopy bowel preparation with either sodium phosphate or polyethylene glycol electrolyte lavage.	2001 Aug	11474387
Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.	2001 Aug	11454912
[Irritable colon].	2001 Aug 20	11530562
Cisapride and the Vanessa Young inquest.	2001 Aug 21	11531044
Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.	2001 Aug-Sep	11569530
Cisapride use in preterms.	2001 Jan	11476059
[Anorexia nervosa or somatic disease].	2001 Jul	11547640
A randomized, double-blind placebo-controlled trial of the effects of the 5-hydroxytriptamine(4) agonist cisapride on the female urinary bladder.	2001 Jul	11483905
Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man.	2001 Jul	11480539
Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography.	2001 Jul	11479406
Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants.	2001 Jul	11474146
Red wine-cisapride interaction: comparison with grapefruit juice.	2001 Jul	11452240
Cisapride improves gallbladder emptying and bile lipid composition in patients with gallstones.	2001 Jul	11446892
Pharmacological characterization of a novel 5-HT4 receptor agonist, TS-951, in vitro.	2001 Jul	11408827
Pneumatosis intestinalis in a patient with polymyositis.	2001 Jul-Aug	11491518
Study of the drug-drug interaction between simvastatin and cisapride in man.	2001 Jun	11497338
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.	2001 Jun	11419817
Cisapride associated with QTc prolongation in very low birth weight preterm infants.	2001 Jun	11389249
"Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium.	2001 Jun 22	11430924
Effect of cisapride on gastric sensitivity to distension, gastric compliance and duodeno-gastric reflexes in healthy humans.	2001 Jun-Jul	11529652
Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters.	2001 May	11501334
Drug safety: can simple interventions be effective in a complex world?	2001 May	11501333
Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug.	2001 May	11448055
Mechanisms of cisapride affecting gallbladder motility.	2001 May	11341662
Cisapride and patient information leaflets.	2001 May 1	11341134
Canada needs better drug reporting, says inquest.	2001 May 5	11356458
Update on acute colonic pseudo-obstruction.	2001 Oct	11560803
Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS.	2001 Oct	11489677
The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease.	2001 Sep	11552909
Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial.	2001 Sep	11521984
Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.	2001 Sep	11521983
[Drug therapy of functional dyspepsia. A review based on Cochrane Reviews].	2001 Sep 10	11573368
QT interval effects of cisapride in the clinical setting.	2001 Sep-Oct	11578711

Patents

Sample Use Guides

In Vivo Use Guide

Initiate therapy with one 10 mg tablet or 10 mL of the suspension 4 times daily at least 15 minutes before meals and at bedtime. In some patients the dosage will need to be increased to 20 mg, given as above, to obtain a satisfactory result.

Route of Administration: Oral

In Vitro Use Guide

The addition of Cisapride to the mucosal solution to give a concentration of 6 x 10-5 M caused a transient rise in potential difference (PD, P < 0.05) and short-circuit current (SCC, P < 0.05) with no significant (P > 0.05) change in tissue resistance.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:25:34 UTC 2023` Edited by `admin` on `Sat Dec 16 17:25:34 UTC 2023`
Record UNII	UVL329170W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CISAPRIDE

Official Name

English

CISAPRIDE [HSDB]

Common Name

English

CISAPRIDE [MI]

Common Name

English

CISAPRIDE [JAN]

Common Name

English

R-51619

Code

English

CISAPRIDE [USAN]

Common Name

English

CIS-4-AMINO-5-CHLORO-N-(1-(3-(P-FLUOROPHENOXY)PROPYL)-3-METHOXY-4-PIPERIDYL)-O-ANISAMIDE

Common Name

English

cisapride [INN]

Common Name

English

CISAPRIDE [USP-RS]

Common Name

English

Cisapride [WHO-DD]

Common Name

English

CISAPRIDE [VANDF]

Common Name

English

R-51,619

Code

English

BENZAMIDE, 4-AMINO-5-CHLORO-N-(1-(3-(4-FLUOROPHENOXY)PROPYL)-3-METHOXY-4-PIPERIDINYL)-2-METHOXY-, CIS

Common Name

English

CISAPRIDE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03FA02